Immuneering (IMRX) SVP Finance granted 140,000 stock options at $4.91

Rhea-AI Filing Summary

Immuneering Corp executive Mallory Morales, SVP Finance and Chief Accounting Officer, received a grant of stock options covering 140,000 shares of Class A common stock on February 3, 2026. The options have an exercise price of $4.91 per share and were granted at no cost.

The option award vests in equal monthly installments over four years starting February 1, 2026 and will be fully vested and exercisable on January 1, 2030. Following this grant, Morales beneficially owns 140,000 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Morales Mallory

Role SVP Finance, CAO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	140,000	$0.00	--

Holdings After Transaction: Stock Option — 140,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Morales Mallory

(Last) (First) (Middle)

C/O IMMUNEERING CORPORATION

245 MAIN STREET, SECOND FLOOR

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Immuneering Corp [ IMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP Finance, CAO

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$4.91	02/03/2026		A		140,000		(1)	02/03/2036	Class A Common Stock	140,000	$0	140,000	D

Explanation of Responses:

1. The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2026, and will be fully vested and exercisable on January 1, 2030.

Remarks:

	/s/ Michael D. Bookman, Attorney-in-Fact for Mallory Morales	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Immuneering Corp (IMRX) report for Mallory Morales?

Immuneering Corp reported a stock option grant to SVP Finance and CAO Mallory Morales. She received options for 140,000 shares of Class A common stock on February 3, 2026, as part of equity compensation, rather than buying or selling existing shares in the market.

How many Immuneering Corp (IMRX) shares are covered by Mallory Morales’s new options?

The option grant covers 140,000 shares of Immuneering Corp Class A common stock. These options give Morales the right to purchase that number of shares in the future, subject to vesting and payment of the exercise price set in the award.

What is the exercise price of Mallory Morales’s Immuneering (IMRX) stock options?

The stock options have a $4.91 exercise price per share. This means Morales can choose to buy Immuneering Corp Class A common stock at $4.91 per share once the options vest and become exercisable under the grant’s vesting schedule.

When do Mallory Morales’s Immuneering (IMRX) options vest and become exercisable?

The options vest in equal monthly installments over four years, beginning February 1, 2026. According to the disclosure, they will be fully vested and exercisable on January 1, 2030, assuming continued service through the vesting period.

Is Mallory Morales’s Immuneering (IMRX) option ownership direct or indirect?

The filing shows direct ownership of the options. After the reported grant, Morales beneficially owns 140,000 stock options directly, with no indication of indirect ownership through entities such as trusts, partnerships, or family investment vehicles in the provided disclosure.

What role does Mallory Morales hold at Immuneering Corp (IMRX)?

Mallory Morales serves as SVP Finance and Chief Accounting Officer at Immuneering Corp. The Form 4 identifies her as an officer of the company, rather than a director or 10% owner, and reports this option grant as part of her equity compensation.